Research
Molecular
Differences in risk-benefit perceptions between the FDA and the European Medicines Agency have led to discrepancies in drug approvals.
Understanding these discrepancies can help practitioners navigate medication options across regions.
StrongSupportsmedium confidence
Differences between the US Food and Drug Administration (FDA) and the European Medicines Agency, however, in perceptions of risk-benefit considerations for individual drugs have resulted in discrepancies in approval and/or withdrawal of weight-reducing medications.
Why this rating
The claim is supported by a review of regulatory practices.
Source
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Andrew J. Krentz et al. · Diabetes Obesity and Metabolism · 2016
DOI 10.1111/dom.12657
reviewCited 167×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →